Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

Sponsor
Erasme University Hospital
Study ID
NCT06189820
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • FAPI PET/CT — DIAGNOSTIC_TEST
    In the department of Nuclear Medicine: * Installation in a relax chair after weight and height control * Placement of a venous line in the upper limb after which an infusion of 500ml of 0.9% NaCl is started. * Intravenous injection of 3 MBq/kg (max 300 MBq) of 18F- FAPI 74 or of 2 MBq/kg 68Ga-FAPI46

Study Details

To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.

Key Dates

First listed
Jan 5, 2024
Start date
Mar 9, 2023
Status verified
Nov 2023
Primary completion
Mar 9, 2027
Completion
Mar 9, 2027

Study Design

Enrollment
70 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Primary Outcome Measure

FAPI uptake on PET/CT [ Time Frame: From date of inclusion till date of the second FAPI PET/CT (after 3 months) ]

Central Contacts

Related Studies